Guangzhou Weimi Bio-Tech Co., Ltd. (广州市微米生物科技有限公司) - Innovative Chinese IVD and POCT Solutions Provi

Company Profile (Updated April 2026)

Guangzhou Weimi Bio-Tech Co., Ltd. (广州市微米生物科技有限公司) is a national high-tech enterprise dedicated to the integrated development of in vitro diagnostic (IVD) technology and the point-of-care testing (POCT) industry. Founded on September 13, 2013 in Guangzhou Science City, Huangpu District, Guangdong Province, China, the company is engaged in the research, development, production, and sales of IVD reagents and instruments.

The company is headquartered in Guangzheng Technology Industrial Park / South china New Materials Innovation Park within Guangzhou Science City. It has established a complete modern enterprise management system and built a nationwide marketing network. The company's products are used in over 2,000 large, medium, and small hospitals across China and have received positive feedback from clinical users.

Core Mission: "Making testing more accurate, faster, and more convenient!" (让检测更准、更快、更方便！). The company adheres to the philosophy of quality first, reputation paramount, management-based, and service-oriented operations.

Financing History

Series A (November 2018): Completed with investors Med-Fine Capital (幂方资本), Qianshan Investment (千杉投资), and GenHe Capital (金阖资本), the industry investment fund associated with Guangzhou KingMed Diagnostics Group

Series A+ (September 2020): Completed with GenHe Capital and Med-Fine Capital

Series B (September 2021): Raised RMB 100 million led by CICC Capital (中金资本) through CICC Qide Fund, with participation from Chuangyu Investment (创钰投资), Med-Fine Capital, and Jiahong Medical (佳鸿医疗)

Total Funding Raised: Approximately RMB 115 million

Core Technology Platforms

The company has established an "Integrated Body, Two Wings" (一体两翼) strategic technology platform layout:

Two Wings — High-End Platforms:

- Neuro-Autoimmunity Platform: Multi-fluorescence precision diagnostic technology for neuroimmune diseases, recognized by the Guangdong Provincial Department of Science and Technology as the Guangdong Neuroimmune Disease Multi-Fluorescence Precision Diagnostic Engineering Center

- Flow Cytometry Fluorescence Platform: Advanced multi-parameter fluorescence detection technology

Integrated Body — Conventional Platforms:

- Acridinium Ester Chemiluminescence

- Biochemistry

- Time-Resolved Fluorescence Quantitative

- Indirect Immunofluorescence

- ELISA (Enzyme-Linked Immunosorbent Assay)

- Colloidal Gold Chromatography

Product Portfolio

The company has obtained 175 product registrations (including reagents and instruments) from the National Medical Products Administration (NMPA). Its products cover the following disease areas:

Detection Series

- Inflammation Detection Series: C-reactive protein (CRP), procalcitonin (PCT), serum amyloid A (SAA), ferritin, cytokine detection (flow cytometry and chemiluminescence methods)

- Cardiovascular and Cerebrovascular Disease Series: Comprehensive cardiac and vascular markers

- Obstetrics and Gynecology Series: Prenatal screening, cervical cancer detection (modified acetic acid white solution), vaginal discharge analysis

- Pathogenic Microorganism Detection Series: Respiratory and infectious pathogen detection

- Tumor Detection Series: Vascular endothelial growth factor (VEGF) and other tumor markers

- Diabetes and Nephropathy Series: Metabolic and renal function markers

- Gastrointestinal Bleeding Detection Series

Instruments

- Time-resolved immunofluorescence analyzers

- Chemiluminescence immunoassay analyzers

- Flow cytometry systems

- Colloidal gold Rapid test readers

2026 Latest Developments

New Medical Device Registrations (Q1 2026)

In the first quarter of 2026, the company obtained three Class I medical device product registrations (record filings) from the Guangzhou Municipal Market Supervision Administration:

- Human LeUKocyte Antigen DR Antibody Reagent (Flow Cytometry Method — APC-Cy7)

- CD63 Detection Reagent (Flow Cytometry Method — FITC)

- CD9 Antibody Reagent (Flow Cytometry Method — PE-Cy7)

Talent Expansion (2026)

As of early 2026, the company is actively recruiting academic specialists and sales professionals across multiple cities including Zhengzhou, Chengdu, Shenzhen, Jinan, and Changsha, reflecting continued business expansion and market development efforts.

Certifications and Honors

- National High-Tech Enterprise: Certified and renewed (first certified in 2019, renewed in 2022)

- ISO 13485:2016: British medical device quality management system certification (2019)

- Guangzhou Future Unicorn Enterprise: Recognized in 2023; also selected in the 2022 Guangzhou Future Unicorn Innovative Enterprise List

- Huangpu District Gazelle Enterprise: Recognized in 2023; previously certified as Huangpu District Gazelle Cultivation Enterprise in 2019 and 2020

- Guangzhou "Specialized, Refined, Distinctive, and Innovative" SME: Selected in 2021 for the cultivation program for private enterprises

- Huangpu District "Green+" Enterprise: Certified in 2021

- Future Healthcare 100 Strong — China Innovative Medical Device TOP100: 2021

- China Science and Technology Innovation Summit Innovative Enterprise TOP100: Recognized for outstanding innovation performance

- Guangzhou Industry-University-Research Collaborative Innovation Major Project: Award recipient

- Guangzhou Municipal SME Technology Innovation Fund: Project recipient

- TeACHing Base: Guangzhou University of Chinese Medicine — Weimi Bio-Tech Teaching Base (established 2021)

- COVID-19 Emergency Research Project: Guangzhou Municipal COVID-19 Infection Emergency Joint Research Project successfully completed and accepted in 2020

- Product Innovation Award: Vascular Endothelial Growth Factor (VEGF) Detection Reagent (Immunofluorescence Chromatography Method) won the Gold Award at the 2022 "Innovation Star" Cup China IVD Excellent Innovative Products (awarded in 2023)

Company Basic Information

Corporate Overview

Company Full Name: Guangzhou Weimi Bio-Tech Co., Ltd. (广州市微米生物科技有限公司)

Founded: September 13, 2013

Registered Address: Room D1301, No. 29 Bishan Street, Huangpu District, Guangzhou, Guangdong, China

Office Address: Building A, Room 308, Guangzheng Technology Industrial Park, No. 11 South Yunwu Road, Science City, Huangpu District, Guangzhou, Guangdong, China (also listed as G8-502, South China New Materials Innovation Park, No. 31 Kefeng Road, Science City)

Legal Representative (Business Registration): Wang Boping (汪波平)

Founder / Chairman (Industry Reports): Wang Tao (汪涛) — Note: Industry reports and financing announcements frequently cite Wang Tao as founder and chairman, while business registration records list Wang Boping as legal representative. The relationship between these two names requires further verification.

Company Type: Private Limited Liability Company (Natural Person Investment or Holding)

Industry: Medical Devices / In Vitro Diagnostics (IVD) / Research and Experimental Development

Registered Capital: RMB 26,561,958 (26.56 million), fully paid-in

Unified Social Credit Code: 91440116078417690A

Employees: Approximately 100-499 (per recruitment platforms; 51-100 per some enterprise directories)

Financing Stage: Series B

Estimated Valuation: Approximately RMB 100 million

Official Website: www.weimibio.com

Email: wmbio@weimijia.cn / liangziqing@weimijia.cn

Telephone: +86-020-82350856

Subsidiaries and Affiliates

- Changsha Weimi Bio-Tech Co., Ltd. (长沙市微米生物科技有限公司) — Wholly-owned subsidiary

- Guangzhou Jiayuan Medical Reagent Co., Ltd. (广州市珈源医学试剂有限公司) — Specialized sales and service subsidiary for IVD products

Market Layout

Domestic Market

The company has established a nationwide marketing network covering major provinces and cities across China. Its products have entered over 2,000 hospitals of various sizes and are widely used in clinical laboratories for rapid detection and disease diagnosis.

International Market

The company's business scope includes goods import and export (excluding specially controlled commodities), and it actively explores international market opportunities. The company participates in major industry exhibitions including Arab Health, Medlab Middle East, and CACLP to expand global brand influence.

2026 Outlook and Strategic Priorities

Strategic Focus Areas

- Technology Platform Advancement: Continue strengthening the "Integrated Body, Two Wings" platform layout, with particular focus on neuro-autoimmunity and flow cytometry fluorescence high-end platforms

- Product Pipeline: Develop exclusive new products with significant clinical testing value, expanding coverage across pathogen detection, inflammation, obstetrics/gynecology, cardiovascular/cerebrovascular, and oncology

- Market Expansion: Expand the nationwide sales network and strengthen relationships with tertiary hospitals and clinical laboratories

- Talent Development: Recruit academic specialists and sales professionals to support business growth

- Quality and Certification: Maintain ISO 13485 and high-tech enterprise certifications while pursuing additional product registrations

Competitive Advantages

- Multi-Platform Integration: One of the few domestic companies with eight technology platforms covering both high-end and conventional diagnostic methods

- R&D Capability: Sustained high investment in R&D with a team of doctors, masters, and technical management talents across biotechnology, genetics, microbiology, immunology, and medical laboratory science

- Product Breadth: 175+ registered products covering major disease areas and hospital departments

- Clinical Validation: Products validated in 2,000+ hospitals with positive clinical feedback

- Investor Backing: Strong financial and strategic support from leADINg healthcare investors including CICC Capital, GenHe Capital, and Med-Fine Capital

Contact Information

Headquarters

Address: Building A, Room 308, Guangzheng Technology Industrial Park, No. 11 South Yunwu Road, Science City, Huangpu District, Guangzhou, Guangdong, China
   Tel: +86-020-82350856
   Email: wmbio@weimijia.cn
   Website: www.weimibio.com

Additional Location

Address: Room D1301, No. 29 Bishan Street, Huangpu District, Guangzhou, Guangdong, China
   Registered Capital: RMB 26,561,958

Keywords: Guangzhou Weimi Bio-Tech,Weimi Bio-Tech,微米生物,IVD,POCT,In Vitro Diagnostics,Time-Resolved Immunofluorescence,Flow Cytometry,Chemiluminescence,Colloidal Gold,Inflammation Detection,Cardiovascular Detection,Pathogen Detection,Tumor Detection,Neuro-Autoimmunity,National High-Tech Enterprise,Guangzhou Future Unicorn,Huangpu District Gazelle Enterprise,Guangzhou Science City,Wang Boping,Wang Tao,ISO 13485,CICC Capital,GenHe Capital,Med-Fine Capital